Global Microbiome Therapeutics Market Report 2022: Increasing Focus on Human Microbiome Therapeutics Development from Academics, Researchers & Biotechnology Firms - GlobeNewswire
Dublin, Nov. 22, 2022 (GLOBE NEWSWIRE) -- The "Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,...
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings | Seres Therapeutics
The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.
What is the potential of microbiome-based medicine in the era of precision management? This special issue in @AGA_Gastro is still timely and includes interesting readings in the field, such as major caveats in defining a healthy microbiome: https://t.co/PdjimGbLnz pic.twitter.com/zAUPBCD9x4— GutMicrobiota Health (@GMFHx) November 19, 2022
C Difficile Infection Drug Market Swot Analysis by Key Factors That Shows High Growth in Industry Revenue From - openPR
C Difficile Infection Drug Market 2022 Forecast to 2029 research provides accurate economic global and country level predictions and analyses It provides a comprehensive perspective of the competitive market as well as an in depth supply chain analysis to assist ...
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection - GlobeNewswire
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
2'-Fucosyllactose inhibits proliferation of Clostridioides difficile ATCC 43599 in the CDi-screen, an in vitro model simulating Clostridioides difficile infection
The CDi-screen is suitable for studying C. difficile proliferation in a complex gut ecosystem and for screening for anti-pathogenic interventions that target C. difficile directly and/or indirectly through interactions with the gut microbiota. Different doses of compounds such as in th …
Research Study Confirms Efficacy of Doctor's Biome Signature Probiotics Blend
/PRNewswire/ -- A new in vitro research study conducted by the Eurofins Labs confirmed efficacy of Doctor's Biome proprietary blend of probiotics (10...
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
– Investigational oral microbiome therapeutic was observed to reduce recurrent C. difficile infection (rCDI) after just one recurrence and remained low regardless of diagnostic approach –– Clinical data shows SER-109 is well tolerated, including among people with multiple comorbidities –CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeuti..
Join us as part of the John G. Bartlett Memorial Education Series, in honor of Clostridioides difficile (C. diff) Awareness Month, which is an effort to brin...
SER-109 well-tolerated, reduces recurrent C. difficile infection through 24 weeks
SER-109, an investigational oral microbiome therapeutic, was well-tolerated and durably reduced rates of recurrent Clostridioides difficile infection through 24 weeks, with benefits showing as early as week 2, data show. SER-109 (Seres Therapeutics) is an oral capsule prepared from healthy donor stool containing dormant Firmicute spores that are activated in the lower GI tract. It received orphan
NTCD-M3 for Clostridioides difficile Infections (CDI) Professor Mark Wilcox presents at the Destiny Pharma R&D Investor Update meeting – 18th October 2022 Professor Dale Gerding discusses the threat of C. difficile infections NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile which lacks the genes that can express C. difficile toxins. It is an
.@VedantaBio is a biopharma company pioneering the development of defined bacterial consortia as oral therapies to modulate the #microbiome to treat disease. Its pipeline includes product candidates for #CDiff, #IBD, Gram-negative infections & tumors. https://t.co/zhKTMiqZ73— MTIG (@MTIG_News) November 11, 2022
Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 - Exclusive Report by InsightAce Analytic
/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market...
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660 - PubMed
A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment su …
Apple Polyphenol Extract Suppresses Clostridioides difficile Infection in a Mouse Model - PubMed
Fruits such as apples are a dietary source of polyphenols and have health benefits. We studied the benefits of apple polyphenols in reducing intestinal infections. We explored the potential roles of apple polyphenols in combating Clostridioides difficile-induced intestinal infections by modul …
Imperial partnering with EnteroBiotix to advance microbiome medical treatments | Imperial News | Imperial College London
MICROBIOME MEDICINE - Imperial is partnering with biotechnology company EnteroBiotix on research into the potential of therapies based on the gut bacterial community.
The Role of Microbiome-Based Therapeutics in Clostridioides difficile Infection: Durable, Long-Term Results of RBX2660 - PubMed
A recently published manuscript described findings from a phase 2 open label study of the microbiota-based live biotherapeutic product RBX2660 in patients with two or more previous recurrent Clostridioides difficile infection (rCDI) episodes, and described long-term safety and sustained treatment su …
Infection Research & Development Pipeline - Crestone, Inc.
Our R&D pipeline includes several programs that address areas of significant unmet medical needs including C. diff infection, MRSA, tuberculosis, and more.